Fresenius Kabi announced the launch of Moxifloxacin Injection in the company’s Freeflex delivery system, the first generic version of Bayer’s Avelox Injection.

Moxifloxacin Injection is a quinolone antibiotic indicated for the treatment of adults ≥18 years of age with infections caused by susceptible isolates of the designated microorganisms in acute bacterial sinusitis; acute bacterial exacerbation of chronic bronchitis; community acquired pneumonia; uncomplicated skin and skin structure infections; complicated skin and skin structure infections; and complicated intra-abdominal infections. Freeflex is a non-PVC and non-DEHP flexible bag for infusion solutions using patented port technology and clear labeling.

RELATED: Avelox Approved for Plague Prevention, Treatment

Moxifloxacin Injection is available as a 400mg/250mL strength in 300mL bags in a single-use, ready-to-use Freeflex container.

For more information call (888) 386-1300 or visit